Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 33% Improvement Relative Risk Colchicine  Yadollahzadeh et al.  LATE TREATMENT  RCT Is late treatment with colchicine beneficial for COVID-19? RCT 52 patients in Iran Lower mortality with colchicine (not stat. sig., p=0.54) c19early.org Yadollahzadeh et al., Coronaviruses, Feb 2024 Favors colchicine Favors control

Colchicine with Infliximab Compared to Infliximab in Hospitalized Patients with COVID-19 Pneumonia: An Open-label Randomized Trial

Feb 2024  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.0000001 from 54 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Open-label RCT with 52 severe COVID-19 pneumonia patients showing no significant differences in mortality with colchicine. All patients received infliximab and remdesivir.
Although the 33% lower mortality is not statistically significant, it is consistent with the significant 29% lower mortality [19‑39%] from meta analysis of the 42 mortality results to date.
risk of death, 33.3% lower, RR 0.67, p = 0.54, treatment 6 of 26 (23.1%), control 9 of 26 (34.6%), NNT 8.7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yadollahzadeh et al., 29 Feb 2024, Randomized Controlled Trial, Iran, peer-reviewed, 10 authors, trial IRCT20200325046854N2.
This PaperColchicineAll
Colchicine with Infliximab Compared to Infliximab in Hospitalized Patients with COVID-19 Pneumonia: An Open-label Randomized Trial
Mahdi Yadollahzadeh, Somayyeh Nasiripour, Najmeh Moradi Shahrbabak, Nader Rezaie, Mohsen Farrokhpour, Mehdi Azimi, Shirin Izadi, Farhad Zamani, Maryam Farasatinasab, Hootan Diba
Coronaviruses, doi:10.2174/0126667975271636231109051950
Background: Anti-inflammatory agents have been proposed to improve oxygenation and mortality rates in severe COVID-19 pneumonia. This study has assessed the impact of colchicine as a coadjuvant inflammatory agent to infliximab in adults hospitalized with severe COVID-19 pneumonia. Method: In this randomized, open-label clinical trial, 63 severe COVID-19 pneumonia patients according to the criteria of the National Institutes of Health, 18 to 85 years old, with an increase in TNF-α and IL-6 levels, were randomized to receive colchicine 1 mg for 7 days and infliximab as a single dose of 300 mg on the first day of treatment or infliximab as a single dose of 300 mg on the first day. The primary outcomes assessed were oxygenation parameters (PaO2/FiO2 ratio and lung infiltrate) after seven days, ICU and hospital length of stay, and in-hospital mortality rates. Secondary outcomes included laboratory data and drug safety after 7 days. Result: 52 patients with similar baseline characteristics completed the study. There were no significant differences in oxygenation parameters (PaO2/FiO2 ratio and lung infiltrate) after seven days, median ICU and hospital length of stay, and in-hospital mortality rates between the two groups. Laboratory data showed no differences between both the groups seven days after the treatment. Also, no serious side effects were observed during the study among the two groups, except for one patient, who experienced diarrhea. Conclusion: Our results cannot support the addition of colchicine to promote the improvement of clinical outcomes in severe COVID-19 pneumonia.
CONFLICT OF INTEREST The authors declare no conflict of interest, financial or otherwise.
References
Brunetti, Diawara, Tsai, Colchicine to weather the cytokine storm in hospitalized patients with COVID-19, J Clin Med, doi:10.3390/jcm9092961PMID:32937800
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: The GRECCO-19 randomized clinical trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.13136
Farrokhpour, Rezaie, Moradi, Infliximab and intravenous gammaglobulin in hospitalized severe covid-19 patients in intensive care unit, Arch Iran Med, doi:10.34172/aim.2021.22PMID:33636983
Fisher, Veenith, Slade, Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): A randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial, Lancet Respir Med, doi:10.1016/S2213-2600(21)00460-4PMID:34922649
Ghaith, Gabra, Nafady, Elshawah, Negida et al., A review of the rational and current evidence on colchicine for COVID-19, Curr Pharm Des, doi:10.2174/1381612827666211210142352PMID:34895117
Huang, C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis, Ther Adv Respir Dis
Kow, Lee, Ramachandram, Hasan, Ming et al., The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta-analysis of randomized trials, doi:10.1002/iid3.562
Lim, Pranata, Huang, Yonas, Soeroto et al., Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: Systematic review and meta-analysis, Can J Kidney Heal Dis
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial, RMD Open, doi:10.1136/rmdopen-2020-001455PMID:33542047
Manenti, Maggiore, Fiaccadori, Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study, PLoS One, doi:10.1371/journal.pone.0248276
Nasiripour, Zamani, Farasatinasab, Can colchicine as an old anti-inflammatory agent be effective in COVID-19?, J Clin Pharmacol, doi:10.1002/jcph.1645PMID:32445400
Nawangsih, Kusmala, Rakhmat, Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and metaregression, Int Immunopharmacol, doi:10.1016/j.intimp.2021.107723
Parra-Medina, Sarmiento-Monroy, Rojas-Villarraga, Garavito, Montealegre-Gómez et al., Colchicine as a possible therapeutic option in COVID-19 infection, Clin Rheumatol, doi:10.1007/s10067-020-05247-5PMID:32556936
Patel, Wadhwa, Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19, Biomed Pharmacother, doi:10.1016/j.biopha.2021.111785
Peter, Mark, Enti, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial, MedRxiv
Robinson, Liew, Liew, The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19, Med, doi:10.1016/j.medj.2020.11.005
Salah, Mehta, Meta-analysis of the effect of colchicine on mortality and mechanical ventilation in COVID-19, Am J Cardiol, doi:10.1016/j.amjcard.2021.02.005
Salehzadeh, Pourfarzi, Ataei, The impact of colchicine on the COVID-19 patients; a clinical trial study, Res Square, doi:10.21203/rs.3.rs-69374/v1
Stallmach, Kortgen, Gonnert, Coldewey, Reuken et al., Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series, Crit Care, doi:10.1186/s13054-020-03158-0PMID:32680535
Vrachatis, Giannopoulos, Giotaki, Impact of colchicine on mortality in patients with COVID-19: A metaanalysis, Hellenic J Cardiol, doi:10.1016/j.hjc.2020.11.012
Yonas, Alwi, Pranata, Elevated interleukin levels are associated with higher severity and mortality in COVID 19 -A systematic review, meta-analysis, and meta-regression, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.11.011
{ 'DOI': '10.2174/0126667975271636231109051950', 'ISSN': ['2666-7967'], 'URL': 'http://dx.doi.org/10.2174/0126667975271636231109051950', 'abstract': '<jats:sec>\n' '<jats:title>Background:</jats:title>\n' '<jats:p>Anti-inflammatory agents have been proposed to improve oxygenation and\n' 'mortality rates in severe COVID-19 pneumonia. This study has assessed the impact of ' 'colchicine as\n' 'a coadjuvant inflammatory agent to infliximab in adults hospitalized with severe COVID-19 ' 'pneumonia.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Method:</jats:title>\n' '<jats:p>In this randomized, open-label clinical trial, 63 severe COVID-19 pneumonia patients ' 'according\n' 'to the criteria of the National Institutes of Health, 18 to 85 years old, with an increase ' 'in\n' 'TNF-α and IL-6 levels, were randomized to receive colchicine 1 mg for 7 days and infliximab ' 'as a\n' 'single dose of 300 mg on the first day of treatment or infliximab as a single dose of 300 mg ' 'on the\n' 'first day. The primary outcomes assessed were oxygenation parameters (PaO2/FiO2 ratio and ' 'lung\n' 'infiltrate) after seven days, ICU and hospital length of stay, and in-hospital mortality ' 'rates. Secondary\n' 'outcomes included laboratory data and drug safety after 7 days.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Result:</jats:title>\n' '<jats:p>52 patients with similar baseline characteristics completed the study. There were no ' 'significant\n' 'differences in oxygenation parameters (PaO2/FiO2 ratio and lung infiltrate) after seven ' 'days,\n' 'median ICU and hospital length of stay, and in-hospital mortality rates between the two ' 'groups. Laboratory\n' 'data showed no differences between both the groups seven days after the treatment. Also,\n' 'no serious side effects were observed during the study among the two groups, except for one ' 'patient,\n' 'who experienced diarrhea.</jats:p>\n' '</jats:sec>\n' '<jats:sec>\n' '<jats:title>Conclusion:</jats:title>\n' '<jats:p>Our results cannot support the addition of colchicine to promote the improvement of\n' 'clinical outcomes in severe COVID-19 pneumonia.</jats:p>\n' '</jats:sec>', 'alternative-id': ['LiveAll1'], 'assertion': [ { 'group': {'label': 'Peer Review Details', 'name': 'peer_review_details'}, 'label': 'Review Status', 'name': 'review_status', 'order': 0, 'value': 'Peer Reviewed'}, { 'group': {'label': 'Peer Review Details', 'name': 'peer_review_details'}, 'label': 'Review Process', 'name': 'review_process', 'order': 1, 'value': 'Single blind'}, { 'group': {'label': 'Plagiarism Screening', 'name': 'plagiarism_screening'}, 'label': 'Screening Status', 'name': 'screening_status', 'order': 0, 'value': 'Checked with iThenticate'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Received', 'name': 'received', 'order': 0, 'value': '2023-07-11'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Revised', 'name': 'revised', 'order': 1, 'value': '2023-09-16'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Accepted', 'name': 'accepted', 'order': 2, 'value': '2023-09-22'}, { 'group': {'label': 'Publication History', 'name': 'publication_history'}, 'label': 'Published', 'name': 'published', 'order': 3, 'value': '2024-03-29'}], 'author': [ { 'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar ' 'Medical and Educational Hospital, Iran University of\n' 'Medical Sciences, Tehran, Iran'}], 'family': 'Yadollahzadeh', 'given': 'Mahdi', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Department of Clinical Pharmacy, Rasul-e Akram Hospital, Iran ' 'University of\n' 'Medical Sciences, Iran'}], 'family': 'Nasiripour', 'given': 'Somayyeh', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar ' 'Medical and Educational Hospital, Iran University of\n' 'Medical Sciences, Tehran, Iran'}], 'family': 'Moradi Shahrbabak', 'given': 'Najmeh', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar ' 'Medical and Educational Hospital, Iran University of\n' 'Medical Sciences, Tehran, Iran'}], 'family': 'Rezaie', 'given': 'Nader', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar ' 'Medical and Educational Hospital, Iran University of\n' 'Medical Sciences, Tehran, Iran'}], 'family': 'Farrokhpour', 'given': 'Mohsen', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar ' 'Medical and Educational Hospital, Iran University of\n' 'Medical Sciences, Tehran, Iran'}], 'family': 'Azimi', 'given': 'Mehdi', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Firoozgar ' 'Medical and Educational Hospital, Iran University of\n' 'Medical Sciences, Tehran, Iran'}], 'family': 'Izadi', 'given': 'Shirin', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Internal Medicine, Gastrointestinal &amp; Liver ' 'Disease Research Center\n' '(GILDRC), Firoozgar Hospital, Iran University of Medical ' 'Sciences, Tehran, Iran'}], 'family': 'Zamani', 'given': 'Farhad', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Clinical Pharmacy,\n' 'School of Pharmacy‐International Campus, Firoozgar Clinical ' 'Research Development Center (FCRDC), Iran University\n' 'of Medical Sciences, Tehran, Iran'}], 'family': 'Farasatinasab', 'given': 'Maryam', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Clinical Pharmacy, Firoozgar Clinical Research ' 'Development Center\n' '(FCRDC), Iran University of Medical Sciences, Tehran, Iran'}], 'family': 'Diba', 'given': 'Hootan', 'sequence': 'additional'}], 'container-title': 'Coronaviruses', 'container-title-short': 'COVID', 'content-domain': {'crossmark-restriction': True, 'domain': ['eurekaselect.com']}, 'created': { 'date-parts': [[2023, 11, 15]], 'date-time': '2023-11-15T14:05:59Z', 'timestamp': 1700057159000}, 'deposited': { 'date-parts': [[2024, 3, 30]], 'date-time': '2024-03-30T12:03:36Z', 'timestamp': 1711800216000}, 'indexed': {'date-parts': [[2024, 3, 30]], 'date-time': '2024-03-30T12:40:50Z', 'timestamp': 1711802450071}, 'is-referenced-by-count': 0, 'issue': '1', 'issued': {'date-parts': [[2024, 2]]}, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2024, 2]]}}, 'language': 'en', 'link': [ { 'URL': 'https://www.eurekaselect.com/article/download?doi=10.2174/0126667975271636231109051950', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.eurekaselect.com/223567/article', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.eurekaselect.com/article/download?doi=10.2174/0126667975271636231109051950', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '965', 'original-title': [], 'prefix': '10.2174', 'published': {'date-parts': [[2024, 2]]}, 'published-print': {'date-parts': [[2024, 2]]}, 'publisher': 'Bentham Science Publishers Ltd.', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': {'primary': {'URL': 'https://www.eurekaselect.com/223567/article'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [ 'Infectious Diseases', 'Virology', 'Pulmonary and Respiratory Medicine', 'Immunology and Microbiology (miscellaneous)'], 'subtitle': [], 'title': 'Colchicine with Infliximab Compared to Infliximab in Hospitalized\n' 'Patients with COVID-19 Pneumonia: An Open-label Randomized Trial', 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.2174/bsp_crossmark_policy', 'volume': '5'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit